GET DAILY SIGNALSModerna (MRNA) Climbs +47% in 30 Days on Oncology Momentum
Key Takeaways
- Moderna (MRNA) rose roughly 47% in the last 30 days, climbing from about $154 in mid-September to near $227, extending a powerful rally that began with a landmark cancer-vaccine readout in August.
- The stock has gained about 281% over the last quarter, driven by positive Phase 3 melanoma data, index inclusion, and growing institutional enthusiasm for mRNA oncology.
- Key catalysts include the INTerpath-001 trial win with partner Merck (MRK), Nasdaq-100 inclusion, a reported NIH cancer-vaccine initiative, and a diagnostics partnership with Tempus AI.
- Investors are watching the detailed Phase 3 data presentation at ESMO and the company's upcoming quarterly results as the next major checkpoints.
- Despite the momentum, Moderna remains unprofitable and trades at a valuation well above most published analyst price targets.
Moderna (MRNA) Company Overview and Market Position
Moderna, Inc. is a Cambridge, Massachusetts-based biotechnology company that pioneered messenger RNA (mRNA) medicines. It rose to prominence with its COVID-19 vaccine, Spikevax, but has spent recent years repositioning itself as a diversified platform company with a pipeline spanning infectious diseases, oncology, and other therapeutic areas. Its approved respiratory franchise now includes an updated flu vaccine, mFlusiva, for adults aged 50 and older.
The company's most closely watched program is intismeran autogene (also known as V940 or mRNA-4157), a personalized mRNA cancer vaccine developed in partnership with Merck. I follow MRNA closely because it represents a test of whether mRNA technology can expand meaningfully beyond COVID-19 into a much larger oncology opportunity. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Moderna (MRNA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Moderna shares advanced roughly 47%, moving from a close near $154 in mid-September to about $227 by mid-October. The move was not a straight line: the stock consolidated in the mid-$140s to $150s during September before breaking higher late in the month and accelerating in early October.
The quarterly trend is even more striking. Approximately three months earlier, in late July, the stock traded around $59. From that level to roughly $227, MRNA gained about 281%. The single most important event in that window occurred on August 19, 2026, when shares surged 177% in one session after the positive melanoma trial readout—the largest one-day percentage gain in the company's history.
What Drove MRNA Stock Price in the Last 30 Days
The 30-day advance reflected a series of reinforcing catalysts rather than a single event. First, in late September the shares began climbing as the market anticipated detailed Phase 3 melanoma data scheduled for presentation at the ESMO Congress. Investor positioning shifted toward the upcoming readout of the full dataset from the INTerpath-001 trial.
In early October, three developments added momentum. On October 8, Tempus AI announced a multi-year collaboration with Moderna and Merck to support the potential commercialization of the personalized cancer vaccine by providing next-generation sequencing and sample logistics. On October 9, a New York Times report described a planned public-private initiative at the National Institutes of Health to accelerate personalized cancer-vaccine research—an effort expected to launch in December and initially focus on pancreatic, liver, and colorectal cancers as well as certain pediatric tumors. That same day, Moderna entered the Nasdaq-100 Index, replacing Warner Bros. Discovery, which typically draws passive index buying and widens institutional coverage.
The combined effect pushed MRNA to a new 52-week high, with shares trading above $220 in mid-October. The rally also continued to pressure short sellers, who had already incurred multibillion-dollar losses following the August announcement.
What Drove MRNA Stock Performance Over the Last Quarter
The dominant driver of the quarterly move was the August 19 announcement that intismeran autogene, combined with Merck's Keytruda, met its primary endpoint of recurrence-free survival and a secondary endpoint of distant metastasis-free survival in the Phase 3 INTerpath-001 trial involving 1,137 patients with high-risk, surgically removed melanoma. It marked the first positive late-stage result for a personalized, mRNA-based cancer therapy.
The result reframed the investment narrative. For years, MRNA had been viewed largely as a declining COVID-19 vaccine franchise; the stock had fallen about 95% from its 2021 record before bottoming near $22 in late 2025. The melanoma win shifted attention toward Moderna's potential as an oncology platform, with additional trials underway in lung, kidney, and bladder cancers. Analysts responded by raising price targets and, in at least one case, upgrading the stock, while peer BioNTech (BNTX) also rallied as the readout validated the broader mRNA cancer-vaccine category.
MRNA Stock Forecast Drivers: What Investors Should Watch Next
Several near-term checkpoints will likely shape sentiment. The detailed Phase 3 melanoma data presented at the ESMO Congress is a key focus, as investors assess the magnitude of the treatment benefit and its read-through to other tumor types. The company's next quarterly earnings report will provide an update on respiratory vaccine revenue, cost discipline, and balance-sheet runway.
Longer term, investors will monitor regulatory filings for intismeran autogene, progress in additional oncology indications, and execution on commercialization and manufacturing. Valuation remains a central debate: MRNA trades at a substantial premium to most published analyst price targets, and the company has yet to return to profitability. Macroeconomic conditions, biotech sector sentiment, and any shift in funding or policy around mRNA research could also influence the stock. These are factors to evaluate carefully rather than signals of a predetermined outcome.
Exploring AI Tools in My Research Process
In my ongoing analysis of fast-moving names like MRNA, I regularly review Tickeron’s Trending AI Robots to compare algorithmic strategies across different timeframes and risk levels. The section highlights top-performing bots that track thousands of tickers, helping me spot approaches that align with current market conditions without replacing my own due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Momentum Indicator for MRNA turns positive, indicating new upward trend
MRNA saw its Momentum Indicator move above the 0 level on September 17, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In 70 of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MRNA just turned positive on October 12, 2026. Looking at past instances where MRNA's MACD turned positive, the stock continued to rise in 30 of 40 cases over the following month. The odds of a continued upward trend are 75%.
Following a +9.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in 212 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 99 of 130 cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
Bearish Trend Analysis
The 10-day RSI Indicator for MRNA moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
MRNA broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.398) is normal, around the industry mean (2.978). P/E Ratio (-28.432) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (25.907) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of transformative medicines for patients
Industry Biotechnology
Advertisement